Cargando…
Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652336/ https://www.ncbi.nlm.nih.gov/pubmed/33166361 http://dx.doi.org/10.1371/journal.pone.0242112 |
_version_ | 1783607691878334464 |
---|---|
author | Wang, Ni Shewade, Hemant Deepak Thekkur, Pruthu Zhang, Hui Yuan, Yanli Wang, Xiaomeng Wang, Xiaolin Sun, Miaomiao Huang, Fei |
author_facet | Wang, Ni Shewade, Hemant Deepak Thekkur, Pruthu Zhang, Hui Yuan, Yanli Wang, Xiaomeng Wang, Xiaolin Sun, Miaomiao Huang, Fei |
author_sort | Wang, Ni |
collection | PubMed |
description | BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missing adherence data were common in the information management system (25%) and shift to directly observed therapy (DOT) based on poor adherence documented by EMMs were seldom. OBJECTIVES: Among people with tuberculosis notified in 30 counties (July-December 2018) where EMM supported self-administered therapy (SAT) was suggested to all eligible (no communication impairment, ambulatory), we assessed the relative differences in unfavourable outcomes and deaths among those started on EMM at baseline (within first month of diagnosis) when compared to SAT alone. METHODS: This was a cohort study using secondary data. We employed an intention to treat analysis, and used modified Poisson regression with robust variance estimates to assess the association. RESULTS: Of 1810 eligible people, 1047 used EMM at baseline and of them, 216 (20.1%) stopped using EMM midway. Of 763 people who did not use EMM at baseline, 267 (35.0%) started using EMM later during the treatment. Among those who started using EMM at baseline, 6.3% [95% CI: 4.9, 8.0] had unfavourable outcomes compared to 6.7% [95% CI: 5.1, 8.8] among those who did not (p = 0.746). Lesser deaths were observed in people who started EMM at baseline when compared to those who did not: 2.5% [95% CI: 1.7, 3.7] versus 3.5% [95% CI: 2.4, 5.2], p = 0.191. The lack of association remained after adjusting for potential confounders (occupation, TB classification and TB category). CONCLUSION: Under programmatic settings, we did not find significant differences in the outcomes. Optimization of EMMs by shifting to DOT when indicated, addressing the issue of missing data and ensuring continuous use is required. |
format | Online Article Text |
id | pubmed-7652336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76523362020-11-18 Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China Wang, Ni Shewade, Hemant Deepak Thekkur, Pruthu Zhang, Hui Yuan, Yanli Wang, Xiaomeng Wang, Xiaolin Sun, Miaomiao Huang, Fei PLoS One Research Article BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missing adherence data were common in the information management system (25%) and shift to directly observed therapy (DOT) based on poor adherence documented by EMMs were seldom. OBJECTIVES: Among people with tuberculosis notified in 30 counties (July-December 2018) where EMM supported self-administered therapy (SAT) was suggested to all eligible (no communication impairment, ambulatory), we assessed the relative differences in unfavourable outcomes and deaths among those started on EMM at baseline (within first month of diagnosis) when compared to SAT alone. METHODS: This was a cohort study using secondary data. We employed an intention to treat analysis, and used modified Poisson regression with robust variance estimates to assess the association. RESULTS: Of 1810 eligible people, 1047 used EMM at baseline and of them, 216 (20.1%) stopped using EMM midway. Of 763 people who did not use EMM at baseline, 267 (35.0%) started using EMM later during the treatment. Among those who started using EMM at baseline, 6.3% [95% CI: 4.9, 8.0] had unfavourable outcomes compared to 6.7% [95% CI: 5.1, 8.8] among those who did not (p = 0.746). Lesser deaths were observed in people who started EMM at baseline when compared to those who did not: 2.5% [95% CI: 1.7, 3.7] versus 3.5% [95% CI: 2.4, 5.2], p = 0.191. The lack of association remained after adjusting for potential confounders (occupation, TB classification and TB category). CONCLUSION: Under programmatic settings, we did not find significant differences in the outcomes. Optimization of EMMs by shifting to DOT when indicated, addressing the issue of missing data and ensuring continuous use is required. Public Library of Science 2020-11-09 /pmc/articles/PMC7652336/ /pubmed/33166361 http://dx.doi.org/10.1371/journal.pone.0242112 Text en © 2020 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wang, Ni Shewade, Hemant Deepak Thekkur, Pruthu Zhang, Hui Yuan, Yanli Wang, Xiaomeng Wang, Xiaolin Sun, Miaomiao Huang, Fei Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title | Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title_full | Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title_fullStr | Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title_full_unstemmed | Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title_short | Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China |
title_sort | do electronic medication monitors improve tuberculosis treatment outcomes? programmatic experience from china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652336/ https://www.ncbi.nlm.nih.gov/pubmed/33166361 http://dx.doi.org/10.1371/journal.pone.0242112 |
work_keys_str_mv | AT wangni doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT shewadehemantdeepak doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT thekkurpruthu doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT zhanghui doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT yuanyanli doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT wangxiaomeng doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT wangxiaolin doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT sunmiaomiao doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina AT huangfei doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina |